BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, July 2, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» NLS Pharmaceutics reports preclinical results from in vitro studies targeting α-synuclein for Parkinson’s disease
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Neurology/psychiatric
NLS Pharmaceutics reports preclinical results from in vitro studies targeting α-synuclein for Parkinson’s disease
June 28, 2024
No Comments
NLS Pharmaceutics Ltd. has announced preclinical results from in vitro studies targeting α-synuclein, specifically the A53T mutation, demonstrating the potential of Aexon Labs Inc.’s compounds for Parkinson’s disease.
BioWorld Science
Neurology/psychiatric